Table 1.
Characteristics of patients admitted for irAE before and after SIC Service implementation
| Characteristic | Pre-SIC* | Post-SIC† | P value‡ |
| (n=127 patients) | (n=122 patients) | ||
| Age, mean (SD), years | 62.6 (13.9) | 64.6 (11.1) | 0.216 |
| Female sex | 44 (34.7%) | 55 (45.1%) | 0.093 |
| Cancer type | |||
| Melanoma | 48 (37.8%) | 31 (25.4%) | 0.156 |
| Thoracic | 35 (27.6%) | 38 (31.2%) | |
| Gastrointestinal | 14 (11.0%) | 26. (21.3%) | |
| Genitourinary | 8 (6.3%) | 9 (7.4%) | |
| Hematologic | 3 (2.4%) | 7 (5.7%) | |
| Gynecologic | 5 (3.9%) | 3 (2.5%) | |
| Head and neck | 5 (3.9%) | 2 (1.6%) | |
| Neurologic | 3 (2.4%) | 4 (3.3%) | |
| Breast | 5 (3.9%) | 2 (1.6%) | |
| Sarcoma | 1 (0.8%) | 0 | |
| ICI type | |||
| CTLA-4 | 9 (7.1%) | 3 (2.5%) | 0.147 |
| PD-1 | 84 (66.1%) | 92 (75.4%) | |
| PD-L1 | 8 (6.3%) | 10 (8.2%) | |
| CTLA-4+PD-1 | 26 (20.5%) | 17 (13.9%) | |
| irAE type | |||
| Allergy | 3 (2.4%) | 1 (0.8%) | 0.311 |
| Cardiac | 9 (7.1%) | 11 (9.0%) | |
| Dermatologic | 9 (7.1%) | 3 (2.5%) | |
| Endocrine | 15 (11.8%) | 13 (10.7%) | |
| Gastrointestinal | 28 (22.1%) | 20 (16.4%) | |
| Hepatic | 20 (15.8%) | 23 (18.9%) | |
| Hematologic | 4 (3.2%) | 2 (1.6%) | |
| Neurologic | 10 (7.9%) | 14 (11.5%) | |
| Pulmonary | 26 (20.5%) | 26 (21.3%) | |
| Renal | 1 (0.8%) | 7 (5.7%) | |
| Rheumatologic | 2 (1.6%) | 2 (1.6%) |
*Data are presented as number (percentage) of patients, unless otherwise indicated; pre-SIC date range is April 2, 2016–October 2, 2017.
†Data are presented as number (percentage) of patients, unless otherwise indicated; post-SIC date range is October 3, 2017–October 24, 2018.
‡Unpaired t-test for continuous data; Pearson χ2 test for categorical data.
CTLA-4, cytotoxic T-lymphocyte antigen-4; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; SIC, Severe Immunotherapy Complications.